Chronic treatment of curcumin improves hepatic lipid metabolism and alleviates the renal damage in adenine-induced chronic kidney disease in Sprague-Dawley rats

Abstract

BackgroundChronic kidney disease (CKD), including nephrotic syndrome, is a major cause of cardiovascular morbidity and mortality. The literature indicates that CKD is associated with profound lipid disorders due to the dysregulation of lipoprotein metabolism which progresses kidney disease. The objective of this study is to evaluate the protective effects of curcumin on dyslipidaemia associated with adenine-induced chronic kidney disease in rats.MethodsMale SD rats (n = 29) were divided into 5 groups for 24 days: normal control (n = 5, normal diet), CKD control (n = 6, 0.75% w/w adenine-supplemented diet), CUR 50 (n = 6, 50 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet), CUR 100 (n = 6, 100 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet), and CUR 150 (n = 6, 150 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet). The serum and tissue lipid profile, as well as the kidney function test, were measured using commercial diagnostic kits.ResultsThe marked rise in total cholesterol, low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids in serum, as well as hepatic cholesterol, triglyceride and free fatty acids of CKD control rats were significantly protected by curcumin co-treatment (at the dose of 50, 100 and 150 mg/kg). Furthermore, curcumin significantly increased the serum high-density lipoprotein (HDL) cholesterol compared to the CKD control rats but did not attenuate the CKD-induced weight retardation. Mathematical computational analysis revealed that curcumin significantly reduced indicators for the risk of atherosclerotic lesions (atherogenic index) and coronary atherogenesis (coronary risk index). In addition, curcumin improved kidney function as shown by the reduction in proteinuria and improvement in creatinine clearance.ConclusionThe results provide new scientific evidence for the use of curcumin in CKD-associated dyslipidaemia and substantiates the traditional use of curcumin in preventing kidney damage.

Effects of Curcumin on the Renal Toxicity Induced by Ochratoxin A in Rats

“…The effects of CURC on renal damage have been investigated in animal models, both in vivo and in vitro. Chronic supplementation of CURC has been shown to protect renal damage in various chemically-induced nephrotoxicity and renal injury models [57]. Our morphologic results support the hypothesis that CURC, as other antioxidants [27], reduces glomerular and tubular damage, kidney inflammation and tubulointerstitial fibrosis in rats, potentially preserving kidney function.…”

Effect of Curcumin Nanoemulsions Stabilized with MAG and DAG-MCFAs in a Fructose-Induced Hepatic Steatosis Rat Model

“…In this study, no significant changes were observed in HDL levels in the cNE-MCFA group. In a report published by Ghelani et al (2019) [ 51 ], SD rats with adenine-supplemented diets and three different curcumin concentrations (50, 100, and 150 mg) for 24 days were evaluated; the data revealed that only the 100 and 150 mg/kg doses increased HDL levels, attributing the effect to the concentration of curcumin; however, the NE-MCFA group showed a slight increase in HDL levels. Zhang et al (2016) [ 52 ] determined that the use of MCT increased HDL and decreased serum bile acid levels when compared to long chain triacylglycerides.…”

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

“…The first discovered pharmacological activity of curcumin is an antibacterial effect, found in 1949 [ 29 ]. Further studies focused on revealing other therapeutic and biological activities of curcumin including antiproliferative [ 30 ], antimetastatic [ 31 ], antioxidant [ 32 ], anti-inflammatory [ 33 ], antidiabetic [ 34 ], antiangiogenic [ 35 ], immunomodulatory [ 36 ], antitumor [ 37 ], antiatherosclerotic [ 38 ] and a lipid lowering effect [ 39 ] and regulating blood pressure [ 40 ].…”